Dreampath and Thermofisher scientific have signed a multi-year Agreement to commercialize Dreampath’s “FINA”, the first fully automated block management solution in pathology.

“We are thrilled about this partnership and about the commercial impact that Thermo will have in key Countries such as USA and China. With this Agreement we are much stronger and can continue bringing innovative solutions to market”, says Pablo Jordan, Dreampath’s CEO.